# UHS earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/UHS) · [Earnings tab](https://www.lopjlb.com/stock/UHS?tab=earnings)

Updated: 2026-07-27T01:50:49

Quarters analyzed: 8

## Cross-quarter narrative

Across eight quarterly CallCards UHS moved from a strong Q2‑2024 earnings beat and modest guidance lift to a pattern of accelerating acute‑care revenue (up 2.4% YoY in Q1‑2025, 5.7% same‑facility in Q2‑2025, 9.6% revenue growth in Q1‑2026) and expanding capital spend on new hospitals. Behavioral volumes have been volatile—flat early in 2025, a March acceleration, then a modest 1.2% increase in Q2‑2025, with management still targeting 2.5‑3% annual growth. Medicaid supplemental programs remain a recurring uncertainty, especially in Tennessee and D.C., while new DPP legislation adds a $360‑400 M head‑wind. Share‑repurchase activity intensified, growing from a $1 B authorization in 2024 to $1.5 B new authority in Q3‑2025 and ongoing buybacks in 2026. Regulatory risks surfaced, notably California psychiatric staffing rules and exchange‑volume declines, alongside weather‑related volume dips. Capital projects progressed: West Henderson Hospital delivered, Cedar Hill opened and later turned profitable, and multiple de‑novo Florida, California and Nevada facilities were launched. Technology investments such as AI‑driven revenue‑cycle tools and the Talkspace acquisition entered the pipeline in Q1‑2026, signaling a shift toward outpatient behavioral growth.

## Latest CallCard · Q1

UHS Q1 2026: revenue +9.6%, adj EBITDA +8.4%, adj EPS +16.1%; Talkspace acquisition announced to accelerate behavioral outpatient strategy; guidance reiterated; AI deployment in revenue cycle; acute volumes hit by flu/weather; share buybacks active.','tone': {'mgmt': 0.3, 'mgmt_rationale': 'Manageme

**Guidance:** vague

**Tone:** mgmt 0 · Q&A pressure 0 · divergence 0

## Quarter one-liners

- **2026 Q1:** UHS Q1 2026: revenue +9.6%, adj EBITDA +8.4%, adj EPS +16.1%; Talkspace acquisition announced to accelerate behavioral outpatient strategy; guidance reiterated; AI deployment in revenue cycle; acute volumes hit by flu/weather; share buybacks active.','tone': {'mgmt': 0.3, 'mgmt_rationale': 'Manageme
- **2025 Q4:** UHS posted solid Q4 2025 results, projects modest 2026 growth, but flags exchange volume declines, California staffing regs and winter‑storm impacts as near‑term risks.
- **2025 Q3:** UHS raised 2025 EPS guidance 6% to $21.80 on strong acute care growth, $90M DC Medicaid boost, and behavioral volume inflection; Cedar Hill turning profitable, Florida hospital on track for 2026; buybacks accelerated with $1.5B new authorization. OB3 Medicaid risk looms ($420-470M by 2032). Exchange
- **2025 Q2:** UHS Q2 2025: EPS guidance raised 7% to $20.50 on higher DPP reimbursement; acute care revenue +5.7% same-facility, behavioral pricing +4.2% but volume +1.2% below target; Cedar Hill certification delayed causing $50M EBITDA drag in 2025; Medicaid DPP legislation poses $360-400M annual headwind by 20
- **2025 Q1:** UHS Q1 beat expectations with 5% acute revenue growth, 21% EBITDA growth; behavioral volumes flat but March acceleration supports 2.5-3% full-year target; Medicaid supplemental uncertainty persists for TN/DC; guidance reiterated. Cash flow impacted by supplemental payment delays. Tariff exposure lim
- **2024 Q4:** UHS posted modest Q4 2024 growth, highlighted Medicaid supplemental gains, expense control, opened a new acute hospital and kept 2025 EBITDA guidance mid‑single‑digit despite Medicaid reimbursement uncertainty.
- **2024 Q3:** —
- **2024 Q2:** UHS Q2 2024: EPS beat, guidance raised 17% to $15.80; acute volumes moderating, behavioral labor challenges persist; $1B buyback authorized; new supplemental programs pending in TN and DC.','tone': {'mgmt': 0.7, 'mgmt_rationale': 'Management highlighted strong Q2 results, 37% acute EBITDA growth, 13

## Theme arcs

- **Acute care revenue growth** (improving): Revenue grew from low‑single‑digit to double‑digit percentages, supporting higher EPS guidance each quarter.
- **Behavioral volume trajectory** (stable): Volumes remain near target but fluctuate seasonally; March acceleration offset earlier flat performance.
- **Medicaid supplemental uncertainty** (deteriorating): Pending approvals in TN and DC persist; DPP legislation adds new head‑wind.
- **Capital expansion** (new): New acute hospitals opened and multiple de‑novo projects announced, expanding inpatient capacity.
- **Share repurchase activity** (improving): Buyback program grew from $1 B authorization to $1.5 B new authority and remains active.
- **Regulatory & external risk exposure** (deteriorating): California staffing regs, exchange volume decline, tariff exposure, and provider‑tax risk emerged.
- **Technology and AI deployment** (new): AI revenue‑cycle tools and Talkspace acquisition aim to boost outpatient behavioral services.

## Guidance path

2024 Q2:vague → 2024 Q3:vague → 2024 Q4:maintained → 2025 Q1:maintained → 2025 Q2:vague → 2025 Q3:vague → 2025 Q4:maintained → 2026 Q1:vague

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/UHS`